Showing results (1481-1490 of 1,518) with videos related to
Sort By:
Pageof 152
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.European Urology|June 2, 2012
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trialA Karim Kader, Jielin Sun, Brian H Reck, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)M Janning, J Süptitz, C Albers-Leischner, et al.Clinical Lung Cancer|March 23, 2023
The EU-funded I<sup>3</sup>LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With ImmunotherapyArsela Prelaj, Monica Ganzinelli, Francesco Trovo', et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European expertsP M Putora, G F Fischer, M Früh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.Pageof 152